Know Cancer

or
forgot password

Electromagnetic Tracking of Devices During Biopsy Procedures


N/A
18 Years
N/A
Not Enrolling
Both
Liver Tumors

Thank you

Trial Information

Electromagnetic Tracking of Devices During Biopsy Procedures


The purpose of the trial is to evaluate the differences between PercuNav assisted and
unassisted biopsy. The primary objective of this study is to assess and quantify any
differences between assisted and unassisted CT guided biopsy procedures of the liver with
respect to radiation dose.

The secondary objectives of this study are to assess and quantify any differences between
assisted and unassisted CT guided biopsy procedures with respect to:

- Total procedure time

- Accuracy of needle targeting (distance from defined target on PercuNav and angle of
entry)

- Number of needle passes

- Target registration error (TRE- distance between "virtual" needle position (tracking
data) and the actual needle position (CT confirmation scan))

The study will consist of 50 patients from 1 site. The expected completion time for
enrollment is 3 months, but will depend on the ability of the clinic to enroll patients.
There are two arms in the study. An Unassisted Biopsy Control arm (physician and patient
blinded to needle positioning using PercuNav system) and Assisted Biopsy (Physician not
blinded to needle positioning using PercuNav). Patients will be randomized to each arm.

The PercuNav provides real-time, three-dimensional visualization and navigation tools for
all stages of diagnosis and surgery including pre-procedure planning and intra-procedure
navigation. PercuNav transforms two-dimensional patient images (scan sets), derived from CT,
PET/CT and MRI into dynamic representations on which a tool can be navigated and fused with
ultrasound. The system performs spatial mapping from one image space to another image space
or from image space to physical space (registration) allowing the physician to correlate
scan sets with each other and to the patient.

For this trial, each patient will have a pre-procedure CT image set of the area of interest.
The image set should display the patient in the same position that the biopsy will be
performed in, although not requisite.

Unassisted Biopsy - CONTROL GROUP (Physician blinded to PercuNav system):

The tracking device will be placed on the patient's skin at the desired point of entry.
Without displaying the PercuNav screen to the physician, a screen capture will be taken to
record the approach path. At the point of insertion, the time stamp will be recorded and the
start button will be pressed. Once the physician states they are at the defined target a
screen capture will be taken on the PercuNav and the distance to target and time stamp will
be recorded by pushing the start button again.

The final dose of radiation displayed by the CT scanner will be recorded on the Case Report
Form.

Assisted Biopsy - STUDY GROUP:

The tracking device will be placed on the patient's skin at the desired point of entry.
Without displaying the PercuNav screen to the physician, a screen capture will be taken to
record the approach path. The physician will be shown the PercuNav screen and will correct
the desired approach path and another screen capture will be taken. At the point of
insertion, the time stamp will be recorded and the start button will be pressed. Once the
physician states they are at the defined target a screen capture will be taken on the
PercuNav and the distance to target and time stamp will be recorded.

The final dose of radiation displayed by the CT scanner will be recorded on the Case Report
Form.

The primary study objective is to quantify, in terms of a point estimate and confidence
interval, the treatment effect which characterizes the mean difference in number of CT scans
between the "unassisted" CT and "assisted" CT groups during guided liver biopsy procedures.
More specifically, the goal will be to show with 95% Confidence that the "assisted" CT
procedure leads to 3 fewer scans, on average, than the "unassisted" CT group during guided
liver biopsies.

H0: uT - aT < 3 scans HA: uT - aT >= 3 scans uT = mean number of scans during "unassisted"
CT procedure aT = mean number of scans during "assisted" CT procedure Equivalently, the
desired superiority will have been demonstrated whenever the lower 95% confidence limit on
the difference, "unassisted" CT minus "assisted" CT, exceeds 3 scans.

Primary Endpoint and Objective:

The primary endpoint for this study is the number of CT radiation exposure scans received
during the course of a CT guided liver biopsy procedure. The primary study objective is to
characterize the difference in the number of scans received between the "assisted" and the
"unassisted" CT groups during guided liver biopsy procedures.

The primary measure that will be assessed and quantified is any differences between assisted
and unassisted CT guided liver biopsies with respect to radiation dose.

The secondary measures that will be assessed and quantified are any differences between
assisted and unassisted CT guided procedures with respect to:

- Total procedure time

- Accuracy of needle targeting (distance from defined target on PercuNav and angle of
entry)


Inclusion Criteria:



1. Has had a pre-operative CT scan performed and will be undergoing a biopsy procedure
of the liver;

2. Is over the age of 18;

3. Has the ability to understand and the willingness to sign a written informed consent
form, and complies with the protocol;

4. Has the ability to follow procedural instructions, including, but not limited to,
holding their breath and remaining reasonably motionless during the procedure.

Exclusion Criteria:

1. Was precluded from a biopsy procedure based on standard exclusions;

2. Has an adhesive allergy (due to the application of active fiducials with adhesive
backing);

3. Has a pacemaker or automatic implantable cardiac defibrillator;

4. Has a gross body weight above 180lbs for women and 260lbs for men;

5. Is pregnant

A patient may be excluded after enrollment if any of the following criteria are met:

1. The patient's health and/or safety become jeopardized for any reason making it unsafe
to continue; 2. Technical errors and/or difficulties; 3. Any reasonable rationale put
forth by the physician or investigator 4. Lost to follow up - In-evaluable data

-

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Radiation Dose

Outcome Description:

The primary objective of this study is to assess and quantify any differences between assisted and unassisted CT guided biopsy procedures of the liver with respect to radiation dose.

Outcome Time Frame:

24 hrs

Safety Issue:

No

Principal Investigator

Edward Kim, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mount Sinai School of Medicine

Authority:

United States: Institutional Review Board

Study ID:

2010_MtSinai_BiopTrial_V2

NCT ID:

NCT01403727

Start Date:

November 2011

Completion Date:

May 2013

Related Keywords:

  • Liver Tumors
  • Biopsy of liver tumors
  • Liver Neoplasms

Name

Location

Mount Sinai Medical CenterNew York, New York  10029